Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.
BACKGROUND
Recombinant alpha(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with alpha(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of yeast-derived human recombinant alpha(1)-proteinase inhibitor on human peripheral blood neutrophils and eosinophils were therefore tested in vitro.


METHODS
Human peripheral blood leukocytes were prepared from forearm venous blood and tested for migration toward various preparations of yeast-derived recombinant alpha(1)-proteinase inhibitor in modified Boyden-chamber micropore filter assays.


RESULTS
No direct effects of yeast-derived recombinant human alpha(1)-proteinase inhibitor on in vitro migration of isolated neutrophils or eosinophils were seen.


CONCLUSIONS
The lack of direct chemotactic effects of recombinant human alpha(1)-proteinase inhibitor despite anti-inflammatory effects in other biological activities of leukocytes may contribute to the preserved antibacterial defense mechanisms observed in patients under experimental augmentation therapy with inhaled alpha(1)-proteinase inhibitor.
Mosheimer
Birgit
B
Division of General Internal Medicine, Department of Medicine, Medical University of Innsbruck, A-6020, Innsbruck, Austria.
Alzner
Reinhard
R
Wiedermann
Christian J
CJ
D054441:Cell Migration Assays, Leukocyte; D002634:Chemotaxis, Leukocyte / Q000187:drug effects* / Q000276:immunology; D015194:Diffusion Chambers, Culture; D004804:Eosinophils / Q000276:immunology; D006098:Granulocytes / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D066298:In Vitro Techniques; D009504:Neutrophils / Q000276:immunology; D011656:Pulmonary Emphysema / Q000188:drug therapy / Q000276:immunology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D015003:Yeasts; D000515:alpha 1-Antitrypsin / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*
D007155:Immunologic Factors; D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin